An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: A meta-analysis of randomised controlled trials

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  Sun, Jie ^a   Yuan, Yang ^a   Cai, Rongrong ^a   Sun, Haixia ^a   Zhou, Yi ^a   Wang, Pin ^a   Huang, Rong ^a   Xia, Wenqing ^a   Wang, Shaohua ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; C REACTIVE PROTEIN; CHOLESTEROL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; PLACEBO; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DIET RESTRICTION; DRUG MECHANISM; EMBASE; GLUCOSE METABOLISM; HORMONE METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PROTEIN HOMEOSTASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THERAPY EFFECT; BLOOD; COMBINATION DRUG THERAPY; FEMALE; METABOLISM; POLYCYSTIC OVARY SYNDROME;

C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE; TRIGLYCERIDES;

EID: 84926640381     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007280     Document Type: Article

References (35)

1. Mehrabian F, Khani B, Kelishadi R, et al. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol 2011;62:238-42.
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
3. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med 2008;26:72-84.
4. Ehrmann DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:66-71.
5. Diamanti-Kandarakis E, Kandaraki E, Christakou C, et al. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev 2009;10:431-41.
6. Milewicz A. Reimbursement of metformin for polycystic ovary syndrome. Endokrynol Pol 2013;64:409-14.
7. Bredella MA, McManus S, Misra M. Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2013;79:199-203.
8. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-5.
9. Kazerooni T, Shojaei-Baghini A, Dehbashi S, et al. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 2010;94:2208-13.
10. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011;96:3493-501.
11. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009;94:4938-45.
12. Sathyapalan T, Kilpatrick ES, Coady AM, et al. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2010;72:566-8.
13. Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013;98:4798-807.
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
15. Raja-Khan N, Kunselman AR, Hogeman CS, et al. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril 2011;95:1849-52.
16. Sathyapalan T, Kilpatrick ES, Coady AM, et al. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009;94:103-8.
17. Sathyapalan T, Shepherd J, Coady AM, et al. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2012;97:3951-5.
18. Sathyapalan T, Smith KA, Coady AM, et al. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem 2012;49(Pt 1):80-5.
19. Celik O, Acbay O. Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. J Endocrinol Invest 2012;35:905-10.
20. Karakas SE, Banaszewska B, Spaczynski RZ, et al. Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies. Gynecol Endocrinol 2013;29:483-7.
21. Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes 2012;120:367-75.
22. Ballard KD, Quann EE, Kupchak BR, et al. Dietary carbohydrate restriction improves insulin sensitivity, blood pressure, microvascular function, and cellular adhesion markers in individuals taking statins. Nutr Res 2013;33:905-12.
23. Krysiak R, Okopien B. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis 2012;225:403-7.
24. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
25. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-92.
26. Rocco MB. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 2012;79:883-93.
27. Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281:11039-49.
28. Kobayashi M, Ikegami H, Fujisawa T, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007;56:239-47.
29. Wang L, Huang X, Hu S, et al. Effect of simvastatin on the expression of farnesoid X receptor in diabetic animal models of altered glucose homeostasis. Chin Med J (Engl) 2014;127:218-24.
30. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009;204:483-90.
31. Ide H, Fujiya S, Aanuma Y, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990;12:410-20.
32. Segarra A, Chacon P, Vilardell M, et al. Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Nephron 1996;73:186-90.
33. Yada T, Nakata M, Shiraishi T, et al. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-13.
34. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357-61.
35. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003;26:1681-4.